Shirley X Zhu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1719206/publications.pdf

Version: 2024-02-01

66343 133252 33,062 63 42 59 citations h-index g-index papers 63 63 63 47884 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer. Clinical Cancer Research, 2022, 28, 2094-2109.	7.0	60
2	Topical therapy for regression and melanoma prevention of congenital giant nevi. Cell, 2022, 185, 2071-2085.e12.	28.9	13
3	MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets. Nature Communications, 2022, 13, 2559.	12.8	56
4	CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells. Cancer Discovery, 2021, 11, 2050-2071.	9.4	43
5	Systematic characterization of mutations altering protein degradation in human cancers. Molecular Cell, 2021, 81, 1292-1308.e11.	9.7	36
6	Inhibitory CD161 receptor identified in glioma-infiltrating TÂcells by single-cell analysis. Cell, 2021, 184, 1281-1298.e26.	28.9	210
7	Neural network architecture search with AMBER. Nature Machine Intelligence, 2021, 3, 372-373.	16.0	0
8	CoBRA: Containerized Bioinformatics Workflow for Reproducible ChIP/ATAC-seq Analysis. Genomics, Proteomics and Bioinformatics, 2021, 19, 652-661.	6.9	18
9	A single-cell and spatially resolved atlas of human breast cancers. Nature Genetics, 2021, 53, 1334-1347.	21.4	535
10	InÂvivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target. Cell, 2021, 184, 5357-5374.e22.	28.9	79
11	Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer. Nature Communications, 2021, 12, 5775.	12.8	59
12	FGFR-inhibitor-mediated dismissal of SWI/SNF complexes from YAP-dependent enhancers induces adaptive therapeutic resistance. Nature Cell Biology, 2021, 23, 1187-1198.	10.3	21
13	Stromal cell diversity associated with immune evasion in human tripleâ€negative breast cancer. EMBO Journal, 2020, 39, e104063.	7.8	224
14	Computational Approaches to Modeling Transcription Factor Activity and Gene Regulation. Trends in Biochemical Sciences, 2020, 45, 1094-1095.	7.5	0
15	Integrative analyses of single-cell transcriptome and regulome using MAESTRO. Genome Biology, 2020, 21, 198.	8.8	126
16	Inhibition of MAN2A1 Enhances the Immune Response to Anti–PD-L1 in Human Tumors. Clinical Cancer Research, 2020, 26, 5990-6002.	7.0	28
17	Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy. Nature Cell Biology, 2020, 22, 1064-1075.	10.3	182
18	CRISPR Screens Identify Essential Cell Growth Mediators in BRAF Inhibitor-resistant Melanoma. Genomics, Proteomics and Bioinformatics, 2020, 18, 26-40.	6.9	14

#	Article	IF	CITATIONS
19	Large-scale public data reuse to model immunotherapy response and resistance. Genome Medicine, 2020, 12, 21.	8.2	514
20	Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer. Molecular Cell, 2020, 78, 1096-1113.e8.	9.7	114
21	TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Research, 2020, 48, W509-W514.	14.5	2,546
22	Integrative analysis of pooled CRISPR genetic screens using MAGeCKFlute. Nature Protocols, 2019, 14, 756-780.	12.0	260
23	Cistrome-GO: a web server for functional enrichment analysis of transcription factor ChIP-seq peaks. Nucleic Acids Research, 2019, 47, W206-W211.	14.5	76
24	ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer. Cancer Cell, 2019, 35, 401-413.e6.	16.8	127
25	Targeting the MIF/CXCR7/AKT Signaling Pathway in Castration-Resistant Prostate Cancer. Molecular Cancer Research, 2019, 17, 263-276.	3.4	27
26	Cistrome Data Browser: expanded datasets and new tools for gene regulatory analysis. Nucleic Acids Research, 2019, 47, D729-D735.	14.5	527
27	Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations. Cancer Cell, 2018, 33, 173-186.e5.	16.8	201
28	Genome-Scale Signatures of Gene Interaction from Compound Screens Predict Clinical Efficacy of Targeted Cancer Therapies. Cell Systems, 2018, 6, 343-354.e5.	6.2	40
29	VIPER: Visualization Pipeline for RNA-seq, a Snakemake workflow for efficient and complete RNA-seq analysis. BMC Bioinformatics, 2018, 19, 135.	2.6	156
30	Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nature Medicine, 2018, 24, 1550-1558.	30.7	2,791
31	Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell–rich and exhausted T-effector microenvironment. Blood, 2018, 132, 825-836.	1.4	121
32	Applications of Immunogenomics to Cancer. Cell, 2017, 168, 600-612.	28.9	198
33	Genome-wide identification and characterization of Notch transcription complex–binding sequence-paired sites in leukemia cells. Science Signaling, 2017, 10, .	3 . 6	39
34	Ultrasensitive detection of TCR hypervariable-region sequences in solid-tissue RNA–seq data. Nature Genetics, 2017, 49, 482-483.	21.4	66
35	Cistrome Cancer: A Web Resource for Integrative Gene Regulation Modeling in Cancer. Cancer Research, 2017, 77, e19-e22.	0.9	130
36	TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Research, 2017, 77, e108-e110.	0.9	4,049

#	Article	IF	Citations
37	Cistrome Data Browser: a data portal for ChIP-Seq and chromatin accessibility data in human and mouse. Nucleic Acids Research, 2017, 45, D658-D662.	14.5	451
38	Revisit linear regression-based deconvolution methods for tumor gene expression data. Genome Biology, 2017, 18, 127.	8.8	45
39	ChiLin: a comprehensive ChIP-seq and DNase-seq quality control and analysis pipeline. BMC Bioinformatics, 2016, 17, 404.	2.6	100
40	Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biology, 2016, 17, 174.	8.8	1,768
41	Modeling <i>cis</i> -regulation with a compendium of genome-wide histone H3K27ac profiles. Genome Research, 2016, 26, 1417-1429.	5 . 5	75
42	Snail1-dependent p53 repression regulates expansion and activity of tumour-initiating cells in breast cancer. Nature Cell Biology, 2016, 18, 1221-1232.	10.3	90
43	Landscape of tumor-infiltrating T cell repertoire of human cancers. Nature Genetics, 2016, 48, 725-732.	21.4	288
44	Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. Cancer Cell, 2016, 29, 255-269.	16.8	356
45	Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature, 2016, 529, 413-417.	27.8	490
46	Predicting Anticancer Drug Responses Using a Dual-Layer Integrated Cell Line-Drug Network Model. PLoS Computational Biology, 2015, 11, e1004498.	3.2	152
47	Sequence determinants of improved CRISPR sgRNA design. Genome Research, 2015, 25, 1147-1157.	5 . 5	514
48	Quality control, modeling, and visualization of CRISPR screens with MAGeCK-VISPR. Genome Biology, 2015, 16, 281.	8.8	330
49	Big data mining yields novel insights on cancer. Nature Genetics, 2015, 47, 103-104.	21.4	64
50	Erratum for Verzi et al., Intestinal Master Transcription Factor CDX2 Controls Chromatin Access for Partner Transcription Factor Binding. Molecular and Cellular Biology, 2015, 35, 496-496.	2.3	0
51	Network analysis of gene essentiality in functional genomics experiments. Genome Biology, 2015, 16, 239.	8.8	50
52	NOTCH1–RBPJ complexes drive target gene expression through dynamic interactions with superenhancers. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 705-710.	7.1	218
53	Kidney Cancer Is Characterized by Aberrant Methylation of Tissue-Specific Enhancers That Are Prognostic for Overall Survival. Clinical Cancer Research, 2014, 20, 4349-4360.	7.0	60
54	Lysine-Specific Demethylase 1 Has Dual Functions as a Major Regulator of Androgen Receptor Transcriptional Activity. Cell Reports, 2014, 9, 1618-1627.	6.4	115

#	Article	IF	Citations
55	Active enhancers are delineated de novo during hematopoiesis, with limited lineage fidelity among specified primary blood cells. Genes and Development, 2014, 28, 1827-1839.	5.9	38
56	JARID1B Is a Luminal Lineage-Driving Oncogene in Breast Cancer. Cancer Cell, 2014, 25, 762-777.	16.8	170
57	Identifying and mitigating bias in next-generation sequencing methods for chromatin biology. Nature Reviews Genetics, 2014, 15, 709-721.	16.3	295
58	Discovery of Biomarkers Predictive of GSI Response in Triple-Negative Breast Cancer and Adenoid Cystic Carcinoma. Cancer Discovery, 2014, 4, 1154-1167.	9.4	123
59	PHF8 and REST/NRSF co-occupy gene promoters to regulate proximal gene expression. Scientific Reports, 2014, 4, 5008.	3.3	16
60	ChIP-Chip: Algorithms for Calling Binding Sites. Methods in Molecular Biology, 2009, 556, 165-175.	0.9	2
61	Analysis of ChIP-chip Data on Genome Tiling Microarrays. Frontiers of Statistics, 2009, , 239-257.	0.2	0
62	Model-based Analysis of ChIP-Seq (MACS). Genome Biology, 2008, 9, R137.	9.6	13,517
63	Getting Started in Tiling Microarray Analysis. PLoS Computational Biology, 2007, 3, e183.	3.2	49